Report cover image

Oncology Biomarker Diagnostics, Global, 2024–2030

Publisher Frost & Sullivan
Published Aug 29, 2025
SKU # MC20367891

Description

This research service offers a comprehensive analysis of the global oncology biomarker diagnostics market, which has transformed with the convergence of clinical demand, advances in technology, and strategic collaborations/partnerships coupled with precision medicine initiatives. It categorizes the market by technology (omics, immunoassays, bioinformatics, and liquid biopsy), providing a 6-year revenue forecast and an analysis of key industry participants. Regional analyses are provided for North America; Europe; Asia-Pacific; the Middle East, North Africa, and South Asia; and Latin America.

The report discusses prevalent and emerging business models, analyzes trends in market access and reimbursement for oncology biomarkers, and offers competitive assessments and revenue share analyses. It examines market drivers and restraints, offering insights into development trends, partnerships, and the investment landscape. The report highlights companies developing disruptive NGS and liquid biopsy technology.

Based on technological advancements, business models, and competitive dynamics, the report identifies growth opportunities in this space for market players and other stakeholders. The base year is 2024, and the forecast period is 2025 to 2030.

Table of Contents

How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.